~~<i id='53654950A7'><strike id='53654950A7'><tt id='53654950A7'><pre id='53654950A7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

focus

author：comprehensive 2025-09-27 23:52:56 - browse：5225

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Why some fertility treatments produce more boy babies

Wikipedia

hotspot

entertainment

hotspot

leisure time

hotspot

LungcancerAdobeCHICAGO—DelfiDiagnostics,acompanyseekingtodevelopliquidbiopsyteststohelpscreenforlung

WSS

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

New research sheds light on how often breast cancer is overdiagnosed

Structure Therapeutics oral GLP

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

The world needs the new pandemic treaty

Anthony Fauci pushes back on GOP claims during Covid hearing

knowledge

focus

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

Hospitals need to get ahead of regulations on climate change

The cancer drug shortage isn’t new — and neither are the solutions

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Moonlake's readout produced a cash windfall. Risks remain

Data don't support strong claims for Covid

Duchenne breakthrough therapy leaves behind pioneering families

Ozempic cut risk of death in diabetes patients with chronic kidney disease

The cancer drug shortage isn’t new — and neither are the solutions

'Little Tech' descents on D.C., wanting a say in how AI is regulated

hotspot

Structure Therapeutics oral GLP

FTC loses bid to block Novant's North Carolina hospital merger

Decentralized clinical trials need collaboration to achieve wider use

FDA approves Moderna’s RSV vaccine, its second licensed product

The world needs the new pandemic treaty

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

entertainment

hotspot

leisure time

hotspot